No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BNTC Benitec Biopharma
- 9.4675
- -0.0225-0.24%
Trading May 23 09:47 ET
88.69MMarket Cap-986P/E (TTM)
9.4675High9.0000Low3.25KVolume9.3900Open9.4900Pre Close29.93KTurnover0.05%Turnover RatioLossP/E (Static)9.37MShares10.700052wk High7.71P/B56.88MFloat Cap1.860052wk Low--Dividend TTM6.01MShs Float3939.6222Historical High--Div YieldTTM4.93%Amplitude1.8600Historical Low9.2190Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
FFIE, OGEN and CCLD Among Mid-day Movers
12 Health Care Stocks Moving In Monday's Intraday Session
GainersCareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.6
Express News | Benitec Biopharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 GAAP EPS Results and a Year-over-year Decrease in Q3 Revenue Results
Express News | Benitec Biopharma Q3 2024 Revenue $0 Down From $54,000 YoY
Express News | Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
Express News | Benitec Biopharma Q3 Net Income USD -4.3 Million
Comments
$Benitec Biopharma(BNTC.US$ Benitec Biopharma Inc: Bb-301 Has Been Granted Orphan Drug Designation by US FDA and EMA Committee for Orphan Medicinal Products (Comp)
3
$Benitec Biopharma(BNTC.US$ phase 1 :X
$Benitec Biopharma(BNTC.US$ Benitec Biopharma Reports Positive Interim Clinical Trial Data for First Opmd Subject Treated With Bb-301 in Phase 1B/2a Study
$Benitec Biopharma(BNTC.US$
NEWS
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study
Improvements in swallowing function demonstrated in multiple measures following BB-301 administration
No serious adverse events reported, with transient GERD resolved with common medications
Encouraging early clinical trial result...
NEWS
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study
Improvements in swallowing function demonstrated in multiple measures following BB-301 administration
No serious adverse events reported, with transient GERD resolved with common medications
Encouraging early clinical trial result...
$Benitec Biopharma(BNTC.US$ Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg